Correlation Between Viracta Therapeutics and Hillevax

Can any of the company-specific risk be diversified away by investing in both Viracta Therapeutics and Hillevax at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Viracta Therapeutics and Hillevax into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Viracta Therapeutics and Hillevax, you can compare the effects of market volatilities on Viracta Therapeutics and Hillevax and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Viracta Therapeutics with a short position of Hillevax. Check out your portfolio center. Please also check ongoing floating volatility patterns of Viracta Therapeutics and Hillevax.

Diversification Opportunities for Viracta Therapeutics and Hillevax

-0.56

Correlation Coefficient

Viracta Therapeutics  Hillevax

Excellent diversification

The 3 months correlation between Viracta and Hillevax is -0.56. Overlapping area represents the amount of risk that can be diversified away by holding Viracta Therapeutics and Hillevax in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Hillevax and Viracta Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Viracta Therapeutics are associated (or correlated) with Hillevax. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Hillevax has no effect on the direction of Viracta Therapeutics i.e., Viracta Therapeutics and Hillevax go up and down completely randomly.

Pair Corralation between Viracta Therapeutics and Hillevax

Given the investment horizon of 90 days Viracta Therapeutics is expected to under-perform the Hillevax. In addition to that, Viracta Therapeutics is 2.2 times more volatile than Hillevax. It trades about -0.1 of its total potential returns per unit of risk. Hillevax is currently generating about 0.08 per unit of volatility. If you would invest  174.00  in Hillevax on September 5, 2024 and sell it today you would earn a total of  17.00  from holding Hillevax or generate 9.77% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	98.44%
Values	Daily Returns

Viracta Therapeutics  vs.  Hillevax

Viracta Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Viracta Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of conflicting performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Hillevax

Risk-Adjusted Performance

6 of 100

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Hillevax are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Hillevax may actually be approaching a critical reversion point that can send shares even higher in January 2025.

Pair Trading with Viracta Therapeutics and Hillevax

The main advantage of trading using opposite Viracta Therapeutics and Hillevax positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Viracta Therapeutics position performs unexpectedly, Hillevax can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Hillevax will offset losses from the drop in Hillevax's long position.

The idea behind Viracta Therapeutics and Hillevax pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.